2025 Japan Anti-Retroviral Drugs Revenue Opportunities Report
Description
The 2025 Japan Anti-Retroviral Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-retroviral drugs (ARV) market in Japan are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead is the market leader globally and in Japan, holding dominant sales via multiple high-revenue HIV therapies such as Biktarvy, which are central to its portfolio. ViiV Healthcare, a specialist HIV company owned by GlaxoSmithKline, Pfizer, and Shionogi, introduced the first long-acting injectable treatment (Vocabria/Cabenuva) approved in Japan, emphasizing innovation in long-acting therapies that reduce dosing frequency from daily to monthly or bimonthly injections.
Janssen Pharmaceuticals, part of Johnson & Johnson, actively collaborates with ViiV Healthcare on integrase inhibitor-based treatments, while Merck co-develops new regimens such as once-weekly oral treatments to diversify options for HIV patients. Shionogi, a Japanese company partnering with ViiV Healthcare, significantly contributes to the Japanese market by co-developing drugs like dolutegravir (marketed as Tivicay) and supporting long-acting injectables, enhancing adherence and patient satisfaction in Japan’s HIV treatment landscape. These companies drive Japan’s ARV market expansion through innovative long-acting injectables, lifecycle management, and strategic collaborations.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-retroviral drugs (ARV) market in Japan are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead is the market leader globally and in Japan, holding dominant sales via multiple high-revenue HIV therapies such as Biktarvy, which are central to its portfolio. ViiV Healthcare, a specialist HIV company owned by GlaxoSmithKline, Pfizer, and Shionogi, introduced the first long-acting injectable treatment (Vocabria/Cabenuva) approved in Japan, emphasizing innovation in long-acting therapies that reduce dosing frequency from daily to monthly or bimonthly injections.
Janssen Pharmaceuticals, part of Johnson & Johnson, actively collaborates with ViiV Healthcare on integrase inhibitor-based treatments, while Merck co-develops new regimens such as once-weekly oral treatments to diversify options for HIV patients. Shionogi, a Japanese company partnering with ViiV Healthcare, significantly contributes to the Japanese market by co-developing drugs like dolutegravir (marketed as Tivicay) and supporting long-acting injectables, enhancing adherence and patient satisfaction in Japan’s HIV treatment landscape. These companies drive Japan’s ARV market expansion through innovative long-acting injectables, lifecycle management, and strategic collaborations.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
